NCL Technology Ventures
London specialist healthcare investor funding early-stage therapeutics, medtech and digital health companies
- Venture capital
- London
- Type
- Venture capital
- Based in
- London
- Stages
- Pre-seed, Seed, Series A, Series B+
- Sector focus
- Fintech, Healthtech
- Cheque size
- €1.5M–€3M
- Fund size
- Undisclosed
- Founded
- 2015
- Website
- nclim.co.uk
NCL Investment Management, the trading name of NCL Technology Ventures Ltd, is a specialist healthcare investor authorised by the Financial Conduct Authority. It provides equity and operational support to early-stage companies whose technologies aim to prevent, treat or cure disease. Areas of interest include immunology and autoimmune conditions, infectious disease, oncology, women's health and digital health. Its portfolio spans therapeutics and medtech businesses such as TC BioPharm, Centauri Therapeutics, Emteq Labs, Ampersand Health and Curesponse. Managing Partner Jerry Biggs set up the investment management business in 2015. The firm is headquartered in London, with a satellite office in New Haven, Connecticut.
← All investors · Is this your organisation? Request an update
More investors in the directory
The Craftory
Purpose-driven consumer packaged goods brands with category-changing potential
Symvan Capital
EIS and SEIS funds backing B2B SaaS and technology companies from seed to exit
Grafton Capital
Growth capital for European software, AI and tech-enabled businesses
Blackfinch Ventures
EIS and VCT investment in early and growth-stage UK technology businesses
The Conduit Connect
Impact-led UK startups from pre-seed to Series A in climate, health and financial resilience
TrueSight Ventures
Angel-sized cheques at pre-seed and seed, sector-agnostic, into technology companies
Subscribe to Newsletter
Join me on this exciting journey as we explore the boundless world of web design together.